John P O'Donnell (John O'Donnell)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Venues

Future microbiology

ACS infectious diseases

Antimicrobial agents and chemotherapy

Journal of medicinal chemistry

Entasis Therapeutics Inc

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Entasis Therapeutics Inc May 01 2015

United States

Vice-President :: DMPK

Publications

Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology 19 (7) (2024)
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology 19 (7) (2024)
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology (2024)
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology 19 (7) (2024)
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology (2024)
John P O'Donnell, Angela Tanudra, April Chen, Alita A Miller, Sarah M McLeod, Rubén Tommasi
In vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex. Antimicrobial agents and chemotherapy (2023)
John P O'Donnell, Angela Tanudra, April Chen, Joseph Newman, Sarah M McLeod, Rubén Tommasi
In vivo dose response and efficacy of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex. Antimicrobial agents and chemotherapy (2023)
John P O'Donnell, Angela Tanudra, April Chen, Daniel Hines, Rubén A Tommasi, John P Mueller
Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282. ACS infectious diseases 6 (6) (2020)
Thomas F Durand-Réville, Janelle Comita-Prevoir, Jing Zhang, Xiaoyun Wu, Tricia L May-Dracka, Jan Antoinette C Romero, Frank Wu, April Chen, Adam B Shapiro, Nicole M Carter, Sarah M McLeod, Robert A Giacobbe, Jeroen C Verheijen, Sushmita D Lahiri, Michael D Sacco, Yu Chen, John P O'Donnell, Alita A Miller, John P Mueller, Rubén A Tommasi
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases. Journal of medicinal chemistry 63 (21) (2020)
Patricia A Bradford, Alita A Miller, John P O'Donnell, John P Mueller
Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates. ACS infectious diseases 6 (6) (2020)

John P O'Donnell.css-eqlu8i{font-size:small;padding-left:4px;} (John O'Donnell)

Publication Activity (10 Years)

Top Topics

Top Venues

John P O'Donnell (John O'Donnell)